AVENTURA, FL — Abarca, a pharmacy benefit manager (PBM) that is disrupting the industry with an entirely new approach to technology and business practices, today announced the relaunch of RxTarget™ with a reward-for-performance program for pharmacies. This initiative is powered by Darwin, Abarca’s smarter PBM platform, and managed through a clinical module of the same name.
“Improving outcomes for members requires buy-in from every level of care,” said Jason Borschow, President & CEO of Abarca. “By leveraging Darwin’s advanced analytic capabilities and giving pharmacies new tools and incentives, RxTarget™ is a new way to achieve better member health.”
While traditional direct and indirect remuneration (DIR) programs are often aimed at penalizing pharmacies, RxTarget™ is built on a bonus-for-performance approach and focuses on quality measures that impact patient outcomes. Through one year of pilot testing, RxTarget™ has been proven to extend the adherence curve across all conditions (Exhibit A).
Based on CMS Star Ratings, and executed using Darwin’s industry-leading reporting capabilities, this program also allows pharmacies to contribute more meaningfully to health plans’ performance. By giving pharmacies access to a sophisticated online platform and the ability to effectively prioritize and track members, the RxTarget™ program empowers and incentivizes pharmacies to make interventions, improve adherence, and deliver benefits for all parties involved.
The RxTarget™ module is just one of the clinical tools that are available to license individually from Darwin. This platform integrates claims processing, pharmacy network, prior authorizations, clinical programs, Medicare and Medicaid compliance, rebate management, and other critical PBM work streams into a single, fast, friendly interface. Invoicing, payments, and all other financial functions can be seamlessly integrated into a PBM’s general ledger, fully automating the accounting cycle, and dramatically reducing overhead.
To learn more about RxTarget™, click here.